Jommi C - Search Results

1

[Establishing the value of new drugs in Italy.].

Villa F, Jommi C, Altamura G, Antignani S, Cangini A, Fortino I, Melazzini M, Trotta F, Tafuri G. Villa F, et al. Among authors: jommi c. Recenti Prog Med. 2020 Feb;111(2):65-69. doi: 10.1701/3309.32795. Recenti Prog Med. 2020. PMID: 32089554 Italian.

2

Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.

Villa F, Tutone M, Altamura G, Antignani S, Cangini A, Fortino I, Melazzini M, Trotta F, Tafuri G, Jommi C. Villa F, et al. Among authors: jommi c. Health Policy. 2019 Jun;123(6):595-600. doi: 10.1016/j.healthpol.2019.03.009. Epub 2019 Apr 13. Health Policy. 2019. PMID: 31097207

3

[Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).].

Jommi C, Armeni P, Costa F, Alberti C, Bandello F, Bordonaro R, Caprodossi A, Di Maio M, Gaudioso A, Giuliani G, Langella R, Marata AM, Patarnello F, Pinto C, Rasi G, Villa F. Jommi C, et al. Recenti Prog Med. 2021 Nov;112(11):749-756. doi: 10.1701/3696.36853. Recenti Prog Med. 2021. PMID: 34782810 Italian.

4

[Unmet clinical need and new therapeutic options.].

Caprari F, Alfano A, Buzzetti G, Consoli A, de Braud F, Patarnello F, Pitrelli A, Riccaboni M, Rossi G, Samele R, Scaduto D, Viale P, Jommi C, Popoli P. Caprari F, et al. Among authors: jommi c. Recenti Prog Med. 2022 Mar;113(3):161-166. doi: 10.1701/3761.37480. Recenti Prog Med. 2022. PMID: 35315445 Italian.

5

The new pharmaceutical policy in Italy.

Fattore G, Jommi C. Fattore G, et al. Among authors: jommi c. Health Policy. 1998 Oct;46(1):21-41. doi: 10.1016/s0168-8510(98)00047-5. Health Policy. 1998. PMID: 10187653

6

The last decade of Italian pharmaceutical policy: instability or consolidation?

Fattore G, Jommi C. Fattore G, et al. Among authors: jommi c. Pharmacoeconomics. 2008;26(1):5-15. doi: 10.2165/00019053-200826010-00002. Pharmacoeconomics. 2008. PMID: 18088155 Review.

7

Multi-tier drugs assessment in a decentralised health care system. The Italian case-study.

Jommi C, Costa E, Michelon A, Pisacane M, Scroccaro G. Jommi C, et al. Health Policy. 2013 Oct;112(3):241-7. doi: 10.1016/j.healthpol.2013.06.004. Epub 2013 Jul 12. Health Policy. 2013. PMID: 23850166

8

Variations in non-prescription drug consumption and expenditure: Determinants and policy implications.

Otto M, Armeni P, Jommi C. Otto M, et al. Among authors: jommi c. Health Policy. 2018 Jun;122(6):614-620. doi: 10.1016/j.healthpol.2018.01.012. Epub 2018 Jan 31. Health Policy. 2018. PMID: 29478875

9

Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.

Armeni P, Borsoi L, Fornaro G, Jommi C, Grossi F, Costa F. Armeni P, et al. Among authors: jommi c. Clin Ther. 2020 May;42(5):830-847. doi: 10.1016/j.clinthera.2020.03.012. Epub 2020 Apr 27. Clin Ther. 2020. PMID: 32354495

10

Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system.

Galeone C, Bruzzi P, Jommi C. Galeone C, et al. Among authors: jommi c. BMJ Open. 2021 Jan 13;11(1):e041259. doi: 10.1136/bmjopen-2020-041259. BMJ Open. 2021. PMID: 33441356 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page